Market Research Report

World Vaccines Market 2012-2022
cover Published by Visiongain
Published Product code 206669
Content info 199 Pages
Price

Introduction

Abstract

Report Details

Why the vaccine market can expand - you discover its commercial potential

image1

Where is the vaccines sector heading? Visiongain's report shows you forecasted revenues to 2022. You see data, trends, opportunities and industry prospects.

Our new study investigates vaccines for human beings, letting you assess projected sales at overall world market, submarket, product and national level. Many segments hold growth potential.

Analysis of submarkets and products

In addition to the overall market, you see revenue forecasting of four world-level submarkets to 2022:

  • Paediatric vaccines
  • Influenza vaccines
  • Adult prophylactic vaccines
  • Therapeutic vaccines.

Also, how will 12 leading products and branded groups - including Prevnar-13, Pentacel, Gardasil and Fluzone - perform to 2022? Our investigation shows business research and analysis with sales forecasts and discussions.

What are the prospects in leading regions and countries?

There are many commercial opportunities in developed and developing countries. You discover revenue forecasts to 2022 for eleven national markets:

  • US
  • Japan
  • Germany, France, UK, Spain and Italy (EU5)
  • Brazil, Russia, India and China (BRIC).

New products from 2012 onwards will benefit world, regional and national markets.

Coverage of research and development

What about the R&D pipeline? You see developmental trends there:

  • Paediatric applications
  • Influenza
  • HPV
  • Adult prophylactic agents
  • HIV
  • Pneumococcal products
  • Therapeutic vaccines.

Technology and other progress will change the sector. The report explains.

What issues affect the vaccines industry and market?

Our study lets you assess industry trends and outlooks worldwide from 2012. You see many discussions:

  • Manufacturing, storage, distribution and supply
  • Emerging applications, including cancers
  • Payers and pricing
  • Safety and regulators
  • Technologies - antigens, adjuvants and delivery systems
  • Policy, pandemics and other issues.

Leading companies and revenue prospects

From 2012 to 2022, biopharma companies will increase the industry's revenues. More vaccination of adults and use of therapeutic vaccines in cancer treatment will stimulate the market.

The R&D pipeline is strong. Also, leading brands retain potential. Our report predicts strong growth in the market's revenues from 2012 to 2022.

Our work discusses Sanofi Pasteur, Pfizer, GSK, Merck and other vaccine developers and manufacturers. This decade, many opportunities will arise for companies.

Commercial news, developmental trends and sales forecasting

In the report you find revenue forecasting, growth rates and market shares. Also, you see qualitative analyses (SWOT and STEP), R&D and commercial developments. You receive 91 tables, 63 charts and a research interview.

Eight ways World Vaccines Market 2012-2022 helps you

In particular, our study gives you the following knowledge on the topic:

  • Find potential revenues to 2022 for the overall world market and submarkets
  • Discover projected revenues of leading products to 2022
  • See market forecasting to 2022 for US, Japan, Germany, France, UK, Spain and Italy (EU5), Brazil, Russia, India and China (BRIC)
  • Assess companies, discovering activities and outlooks
  • Review R&D pipelines, seeing trends
  • View opinions on the sector, including a research interview
  • Investigate competition and opportunities influencing sales
  • Find out what stimulates and restrains the industry and market.

There you find quantitative and qualitative analyses with independent predictions. You receive information unique to our report, helping you stay informed on business intelligence.

Gain research and analysis for vaccines now

Visiongain's study is for everybody needing industry and market analyses for vaccines. You find data, trends and predictions there.

Table of Contents

Table of Contents

1. Executive Summary

  • 1.1 Overview of Findings
  • 1.2 Report Contents
  • 1.3 Research and Analysis Methods

2. Introduction to the Vaccines Market in 2012

  • 2.1 A Brief History of Vaccines
  • 2.2 How Vaccines Work: The Immune System and Natural Immunity
    • 2.2.1 Vaccines Create Artificial Immunity
  • 2.3 Types of Vaccine
    • 2.3.1 Live, Attenuated Vaccines
    • 2.3.2 Recombinant Live Vaccines
    • 2.3.3 Inactivated Vaccines
    • 2.3.4 Toxoid Vaccines
    • 2.3.5 Subunit Vaccines
    • 2.3.6 Conjugate Vaccines
    • 2.3.7 Recombinant Subunit Vaccines
    • 2.3.8 DNA Vaccines
    • 2.3.9 Recombinant Vector Vaccines
    • 2.3.10 Therapeutic Vaccines

3. World Vaccines Market: Overview 2012-2022

  • 3.1 World Vaccines Market Forecast, 2012-2022
  • 3.2 Market Segmentation, 2012-2022
  • 3.3 Leading Companies in the Market, 2012
    • 3.3.1 GlaxoSmithKline, 2012
    • 3.3.2 Sanofi Pasteur, 2012
    • 3.3.3 Pfizer, 2012
    • 3.3.4 Merck, 2012
    • 3.3.5 Novartis, 2012
    • 3.3.6 Other Vaccine Manufacturers, 2012
  • 3.4 The US, Japan and Other Leading National Markets, 2011-2022
    • 3.4.1 EU5 National Market Breakdown, 2011-2022
    • 3.4.2 BRIC National Market Breakdown, 2011-2022

4. Paediatric Vaccines Market, 2012-2022

  • 4.1 Paediatric Vaccines Market Forecast, 2012-2022
  • 4.2 Paediatric Vaccines Market Overview, 2012
    • 4.2.1 Leading Companies in the Paediatric Vaccines Segment, 2012
    • 4.2.2 Regional Variations in the Paediatric Vaccines Segment, 2012
    • 4.2.3 Drivers and Restraints in the Paediatric Vaccines Segment, 2012
  • 4.3 Leading Products in the Paediatric Vaccines Segment, 2012-2022
    • 4.3.1 Prevnar-13 (Pfizer)
      • 4.3.1.1 Drivers and Restraints for Prevnar-13, 2012
      • 4.3.1.2 Market Forecast for Prevnar-13, 2012-2022
    • 4.3.2 Pentacel/Pediacel/Pentaxim/Others (Sanofi Pasteur)
      • 4.3.2.1 Drivers and Restraints for Pentacel/Pediacel/Pentaxim/Others, 2012
      • 4.3.2.2 Market Forecast for Pentacel/Pediacel/Pentaxim/Others, 2012-2022
    • 4.3.3 Proquad/MMR-II/Varivax (Merck)
      • 4.3.3.1 Drivers and Restraints for ProQuad/MMR-II/Varivax 2012
      • 4.3.3.2 Market Forecast for ProQuad/MMR-II/Varivax, 2012-2022
    • 4.3.4 Infanrix/Pediarix/Others (GlaxoSmithKline)
      • 4.3.4.1 Drivers and Restraints for Infanrix/Pediarix/Others, 2012
      • 4.3.4.2 Market Forecast for Infanrix/Pediarix/Others 2012-2022
    • 4.3.5 RotaTeq (Merck)
      • 4.3.5.1 Drivers and Restraints for RotaTeq, 2012
      • 4.3.5.2 Market Forecast for RotaTeq 2012-2022
    • 4.3.6 Other Paediatric Vaccines
  • 4.4 Paediatric Vaccines Pipeline, 2012
    • 4.4.1 Bexsero (Novartis)
    • 4.4.2 Hexaxim (Sanofi Pasteur)
    • 4.4.3 Menveo Infants (Novartis)
    • 4.4.4 MenHibrix (GlaxoSmithKline)
    • 4.4.5 Mosquirix (GlaxoSmithKline)
    • 4.4.6 V419 (Merck)
    • 4.4.7 Ixiaro (Intercell)
    • 4.4.8 Nimenrix (GlaxoSmithKline)
    • 4.4.9 Quadracel (Sanofi Pasteur)
    • 4.4.10 V212 (Merck)
    • 4.4.11 Other Paediatric Vaccine Pipeline Products, 2012
  • 4.5 Segment Revenues by Product, 2012-2022: Summary

5. Influenza Vaccines Market, 2012-2022

  • 5.1 Influenza Vaccines Market Forecast, 2012-2022
  • 5.2 Influenza Vaccines Market Overview, 2012
    • 5.2.1 Leading Companies in the Influenza Vaccines Segment, 2012
    • 5.2.2 Regional Variations in the Influenza Vaccines Segment, 2012
    • 5.2.3 Drivers and Restraints in the Influenza Vaccines Segment, 2012
  • 5.3 Leading Products in the Influenza Vaccines Market, 2012
    • 5.3.1 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others (Sanofi Pasteur)
      • 5.3.1.1 Drivers and Restraints for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others (Sanofi Pasteur), 2012
      • 5.3.1.2 Market Forecast for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2012-2022
    • 5.3.2 Fluarix/Flulaval (GlaxoSmithKline)
      • 5.3.2.1 Drivers and Restraints for Fluarix/Flulaval, 2012
      • 5.3.2.2 Market Forecast for Fluarix/Flulaval, 2012
    • 5.3.3 Other Seasonal Influenza Vaccines, 2012
    • 5.3.4 Pandemic Influenza Vaccines, 2012
  • 5.4 Influenza Vaccines Pipeline, 2012
  • 5.5 Segment Revenues by Product, 2012-2022: Summary

6. Adult Prophylactic Vaccines Market, 2012-2022

  • 6.1 Adult Prophylactic Vaccines Market Forecast, 2012-2022
  • 6.2 Adult Prophylactic Vaccines Market Overview, 2012
    • 6.2.1 Leading Companies in the Adult Prophylactic Vaccines Segment, 2012
    • 6.2.2 Regional Variations in the Adult Prophylactic Vaccines Segment, 2012
    • 6.2.3 Drivers and Restraints in the Adult Prophylactic Vaccines Segment, 2012
  • 6.3 Leading Products in the Adult Prophylactic Vaccines Segment, 2012
    • 6.3.1 Gardasil (Merck)
      • 6.3.1.1 Drivers and Restraints for Gardasil, 2012
      • 6.3.1.2 Market Forecast for Gardasil, 2012-2022
    • 6.3.2 Engerix/Fendrix/Havrix/Twinrix/Ambirix (GlaxoSmithKline)
      • 6.3.2.1 Drivers and Restraints for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012
      • 6.3.2.2 Market Forecast for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012-2022
    • 6.3.3 Cervarix (GlaxoSmithKline)
      • 6.3.3.1 Drivers and Restraints for Cervarix, 2012
      • 6.3.3.2 Market Forecast for Cervarix, 2012-2022
    • 6.3.4 Menactra and Other Meningitis/Pneumonia Vaccines (Sanofi Pasteur)
      • 6.3.4.1 Drivers and Restraints for Menactra and Other Meningitis/Pneumonia Vaccines, 2012
      • 6.3.4.2 Market Forecast for Menactra and Other Meningitis/Pneumonia Vaccines, 2012-2022
    • 6.3.5 Adacel and Other Adult Boosters (Sanofi Pasteur)
      • 6.3.5.1 Drivers and Restraints for Adacel and Other Adult Boosters, 2012
      • 6.3.5.2 Market Forecast for Adacel and Other Adult Boosters, 2012-2022
    • 6.3.6 Other Adult Prophylactic Vaccines
  • 6.4 Adult Prophylactic Vaccines Pipeline, 2012
    • 6.4.1 GSK1437173A (GlaxoSmithKline)
    • 6.4.2 BioThrax (Emergent BioSolutions)
    • 6.4.3 Dengue Fever Vaccine (Sanofi Pasteur)
    • 6.4.4 Heplisav (Dynavax Technologies)
    • 6.4.5 V503 (Merck)
    • 6.4.6 Other Pipeline Adult Prophylactic Vaccines, 2012
  • 6.5 Segment Revenues by Product, 2012-2022: Summary

7. Therapeutic Vaccines Market, 2012-2022

  • 7.1 Therapeutic Vaccines Market Forecast, 2012-2022
  • 7.2 Therapeutic Vaccines Market Overview, 2012
    • 7.2.1 Leading Companies in the Therapeutic Vaccines Segment, 2012
    • 7.2.2 Regional Variations in the Therapeutic Vaccines Segment, 2012
    • 7.2.3 Drivers and Restraints in the Therapeutic Vaccines Segment, 2012
  • 7.3 Provenge: Leading Therapeutic Vaccine, 2011
    • 7.3.1 Drivers and Restraints for Provenge, 2012
    • 7.3.2 Market Forecast for Provenge, 2012-2022
  • 7.4 Therapeutic Vaccines Pipeline, 2012
    • 7.4.1 Abagovamab (Menarini)
    • 7.4.2 MAGE-A3 (GlaxoSmithKline)
    • 7.4.3 BioVaxID (Biovest International)
    • 7.4.4 DCVax-Prostate (NorthWest Biotherapeutics)
    • 7.4.5 GVAX Prostate (Biosante Pharmaceuticals)
    • 7.4.6 HyperAcute Pancreas (New Look Genetics)
    • 7.4.7 IMA901 (Immatics Biotechnology)
    • 7.4.8 Lucanix (Novarx)
    • 7.4.9 M200 Prophage Cancer Vaccine (Agenus)
    • 7.4.10 MVax (Avax Technologies)
    • 7.4.11 Neuvax (Galena Biopharma)
    • 7.4.12 Polyclonal Antibody Stimulator (Cancer Advances)
    • 7.4.13 PROSTVAC (Bavarian Nordic)
    • 7.4.14 Rindopepimut (Celldex Therapeutics)
    • 7.4.15 Stimuvax (EMD Serono)
    • 7.4.16 CVac (Prima Biomed)
    • 7.4.17 Other Therapeutic Cancer Vaccines
    • 7.4.18 Therapeutic Allergy Vaccines
    • 7.4.19 Grass Pollen Extract Sublingual Vaccine (Stallergenes)
    • 7.4.20 Pollinex Quattro (Allergy Therapeutics)
    • 7.4.21 Ragweed Allergy Vaccine (Greer Laboratories)
    • 7.4.22 Ragweed Allergy Vaccine and Grass Pollen Allergy Vaccine (ALK Abello)
    • 7.4.23 Therapeutic Addiction Vaccines
    • 7.4.24 NicVAX (Nabi Biopharmaceuticals)
    • 7.4.25 Therapeutic Chronic Infectious Disease Vaccines
    • 7.4.26 Therapeutic Vaccines for Other Chronic Disease
  • 7.5 Segment Revenues by Product, 2012-2022: Summary

8. Industry Trends, 2012-2022

  • 8.1 Strengths: Vaccines are a Major Ongoing Healthcare Success Story
  • 8.2 Weaknesses: High Costs and Uncertainties in Vaccine Manufacture, Storage and Supply
  • 8.3 Opportunities: Vaccines are Annexing New Therapeutic Areas, and Have Advantages for Market Growth
  • 8.4 Threats: Premium-Priced Vaccines Must Convince Regulators and Payers
  • 8.5 Social: Vaccines Excite Unwarranted Controversy
  • 8.6 Technological: New Antigens, New Adjuvants, New Delivery Systems
  • 8.7 Economic: Rise of the Vaccine-Developing Countries
  • 8.8 Political: Vaccines in National and International Policy

9. Research Interview

  • 9.1 Interview with Dr Louis Picker, Associate Director of OHSU's Vaccine and Gene Therapy Institute
    • 9.1.1 The Basic Challenge of Developing an HIV Vaccine
    • 9.1.2 Early Interception of HIV Infections via Antibodies
    • 9.1.3 Early Interception of HIV Infections via T-Cells
    • 9.1.4 The Use of CMV as a Vaccine Vector
    • 9.1.5 The Effectiveness of the Vaccine in Humans
    • 9.1.6 The Pre-Exposure Prophylactic Use of Anti-Retroviral Drugs as an Alternative Strategy
    • 9.1.7 The Timeline for a Human Trial of the Vaccine

10. Conclusions

  • 10.1 The Vaccine Market Will Show Strong Growth Through to 2022
  • 10.2 Therapeutic Vaccines Will Increase Market Share
  • 10.3 Prevnar-13
  • 10.4 The Vaccine Pipeline is Strong
  • 10.5 Concluding Remarks

List of Tables

  • Table 2.1 Timeline of Key Events in Vaccine Development, c.1000 AD - Present
  • Table 3.1 World Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
  • Table 3.2 World Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
  • Table 3.3 World Vaccines Market Segments: Revenues ($bn), Overall Market Shares (%), 2011
  • Table 3.4 World Vaccines Market Segments: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
  • Table 3.5 World Vaccines Market Segments: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
  • Table 3.6 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
  • Table 3.7 Leading Regions in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
  • Table 3.8 World Vaccines Market Regions: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
  • Table 3.9 World Vaccines Market Regions: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
  • Table 3.10 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
  • Table 3.11 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2022
  • Table 3.12 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2011-2016
  • Table 3.13 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), AGR (%), CAGR (%), Market Shares (%), 2017-2022
  • Table 4.1 Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
  • Table 4.2 Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
  • Table 4.3 Leading Products in the Paediatric Vaccines Market: Revenues ($bn), Market Shares (%), 2011
  • Table 4.4 Leading Products in the Pneumococcal Vaccines Market: Revenues ($bn), Market Shares (%), 2011
  • Table 4.5 Pipeline Pneumococcal Vaccines, 2012
  • Table 4.6 Prevnar-13: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 4.7 Prevnar-13: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.8 Pipeline Paediatric Combination Vaccines, 2012
  • Table 4.9 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 4.10 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.11 ProQuad /MMR-II/Varivax Revenues ($bn), 2009-2011
  • Table 4.12 ProQuad/MMR-II/Varivax: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 4.13 ProQuad/MMR-II/Varivax: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.14 Infanrix/Pediarix/Others Revenues ($bn), AGR (%), Share of Total (%), by Region, 2011
  • Table 4.15 Infanrix/Pediarix/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 4.16 Infanrix/Pediarix/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.17 RotaTeq: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 4.18 RotaTeq: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.19 Other Paediatric Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 4.20 Other Paediatric Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 4.21 Selected Late-Stage Paediatric Vaccines Pipeline, 2012
  • Table 4.22 Selected Phase I and Phase II Paediatric Vaccines Pipeline, 2012
  • Table 4.23 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 4.24 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 5.1 Influenza Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
  • Table 5.2 Influenza Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
  • Table 5.3 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 5.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 5.5 Fluarix/Flulaval: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 5.6 Fluarix/Flulaval: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 5.7 Selected Products in the Influenza Vaccines Pipeline, 2012
  • Table 5.8 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 5.9 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 6.1 Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
  • Table 6.2 Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
  • Table 6.3 Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), Market Shares (%), 2011
  • Table 6.4 Pipeline HPV Vaccines, 2012
  • Table 6.5 Gardasil: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 6.6 Gardasil: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 6.7 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 6.8 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 6.9 Cervarix: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 6.10 Cervarix: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 6.11 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 6.12 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 6.13 Adacel and Other Adult Boosters: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 6.14 Adacel and Other Adult Boosters: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 6.15 Other Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 6.16 Other Adult Prophylactic Vaccines: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 6.17 Selected Late-Stage Adult Prophylactic Vaccines Pipeline, 2012
  • Table 6.18 Selected Prophylactic Anthrax Vaccines Pipeline, 2012
  • Table 6.19 Selected Prophylactic Dengue Fever Vaccines Pipeline, 2012
  • Table 6.20 Selected Prophylactic Hepatitis Vaccines Pipeline, 2012
  • Table 6.21 Selected Prophylactic Malaria Vaccines Pipeline, 2012
  • Table 6.22 Selected Prophylactic Ebola Virus Vaccines Pipeline, 2012
  • Table 6.23 Selected Prophylactic Cytomegalovirus Vaccines Pipeline, 2012
  • Table 6.24 Selected Prophylactic Streptococcal Vaccines Pipeline, 2012
  • Table 6.25 Selected Prophylactic Staphylococcal Vaccines Pipeline, 2012
  • Table 6.26 Selected Other Adult Prophylactic Vaccines in Development, 2012
  • Table 6.27 Selected Other Adult Prophylactic Vaccines in Phase I Development, 2012
  • Table 6.28 Selected Prophylactic HIV Vaccines Pipeline, 2012
  • Table 6.29 Selected Prophylactic HIV Vaccines Phase I Pipeline, 2012
  • Table 6.30 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 6.31 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 7.1 Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2011-2016
  • Table 7.2 Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), Overall Market Shares (%), 2017-2022
  • Table 7.3 Provenge: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 7.4 Provenge: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 7.5 Therapeutic Cancer Vaccines: Late-Stage Pipeline, 2012
  • Table 7.6 Therapeutic Cancer Vaccines: Selected Pipeline Products, 2012
  • Table 7.7 Therapeutic Allergy Vaccines: Selected Pipeline Products, 2012
  • Table 7.8 Therapeutic Addiction Vaccines: Selected Pipeline Products, 2012
  • Table 7.9 Therapeutic Chronic Infectious Disease Vaccines: Selected Pipeline Products, 2012
  • Table 7.10 Therapeutic Vaccines for Other Chronic Diseases: Selected Pipeline Products, 2012
  • Table 7.11 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2011-2016
  • Table 7.12 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), AGR (%), CAGR (%), 2017-2022
  • Table 10.1 Selected Vaccines in Late-Stage Development, 2012

List of Figures

  • Figure 3.1 World Vaccines Market: Revenues ($bn), 2011-2022
  • Figure 3.2 World Vaccines Market Segments: Revenues ($bn), Overall Market Shares (%), 2011
  • Figure 3.3 World Vaccines Market Segments: Revenues ($bn), 2011-2022
  • Figure 3.4 Leading Companies in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
  • Figure 3.5 Leading Regions in the Vaccines Market: Revenues ($bn), Overall Market Shares (%), 2011
  • Figure 3.6 World Vaccines Market Regions: Revenues ($bn), 2011-2022
  • Figure 3.7 EU5 Vaccines Market Breakdown by Country: Revenues ($bn), 2011-2022
  • Figure 3.8 BRIC Vaccines Market Breakdown by Country: Revenues ($bn), 2011-2022
  • Figure 4.1 Paediatric Vaccines Market: Revenues ($bn), 2011-2022
  • Figure 4.2 Drivers and Restraints for Paediatric Vaccines, 2012
  • Figure 4.3 Leading Products in the Paediatric Vaccines Market: Revenues ($bn), Market Shares (%), 2011
  • Figure 4.4 Drivers and Restraints for Prevnar-13, 2012
  • Figure 4.5 Leading Products in the Paediatric Pneumococcal Vaccines Market: Revenues ($bn), Market Shares (%), 2011
  • Figure 4.6 Prevnar-13: Revenues ($bn), 2011-2022
  • Figure 4.7 Drivers and Restraints for Pentacel/Pediacel/Pentaxim/Others, 2012
  • Figure 4.8 Pentacel/Pediacel/Pentaxim/Others: Revenues ($bn), 2011-2022
  • Figure 4.9 ProQuad /MMR-II/Varivax Revenues ($bn), 2009-2011
  • Figure 4.10 Drivers and Restraints for ProQuad/MMR-II/Varivax, 2012
  • Figure 4.11 ProQuad/MMR-II/Varivax: Revenues ($bn), 2011-2022
  • Figure 4.12 Infanrix/Pediarix/Others Revenues ($bn) by Region, 2011
  • Figure 4.13 Drivers and Restraints for Infanrix/Pediarix/Others, 2012
  • Figure 4.14 Infanrix/Pediarix/Others: Revenues ($bn), 2011-2022
  • Figure 4.15 Division of the Rotavirus Vaccine Market, 2011
  • Figure 4.16 Drivers and Restraints for RotaTeq, 2012
  • Figure 4.17 RotaTeq: Revenues ($bn), 2011-2022
  • Figure 4.18 Other Paediatric Vaccines: Revenues, 2011-2022
  • Figure 4.19 Summary of Leading Products in the Paediatric Vaccines Market: Revenues ($bn), 2011-2022
  • Figure 5.1 Influenza Vaccines: Revenues ($bn), 2011-2022
  • Figure 5.2 Drivers and Restraints for Influenza Vaccines, 2012
  • Figure 5.3 Drivers and Restraints for Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others, 2012
  • Figure 5.4 Fluzone/Panenza/Humenza/Intanza/IDflu/Emerflu/Others: Revenues ($bn), 2011-2022
  • Figure 5.5 Drivers and Restraints for Fluarix/Flulaval, 2012
  • Figure 5.6 Fluarix/Flulaval: Revenues ($bn), 2011-2022
  • Figure 5.7 Summary of Leading Products in the Influenza Vaccines Market: Revenues ($bn), 2011-2022
  • Figure 6.1 Adult Prophylactic Vaccines: Revenues ($bn), 2011-2022
  • Figure 6.2 Drivers and Restraints for Adult Prophylactic Vaccines, 2012
  • Figure 6.3 Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), Market Shares (%), 2011
  • Figure 6.4 Drivers and Restraints for Gardasil, 2012
  • Figure 6.5 Gardasil: Revenues ($bn), 2011-2022
  • Figure 6.6 Chronic Hepatitis B: Global Prevalence by Region, 2012
  • Figure 6.7 Drivers and Restraints for Engerix/Fendrix/Havrix/Twinrix/Ambirix, 2012
  • Figure 6.8 Engerix/Fendrix/Havrix/Twinrix/Ambirix: Revenues ($bn), 2011-2022
  • Figure 6.9 HPV Vaccine Market Shares (%), 2011
  • Figure 6.10 Cervarix Sales by Region (%), 2011
  • Figure 6.11 Drivers and Restraints for Cervarix, 2012
  • Figure 6.12 Cervarix: Revenues ($bn), 2011-2022
  • Figure 6.13 Drivers and Restraints for Menactra and Other Meningitis/Pneumonia Vaccines, 2012
  • Figure 6.14 Menactra and Other Meningitis/Pneumonia Vaccines: Revenues ($bn), 2011-2022
  • Figure 6.15 Adult Booster Market Shares (%), 2011
  • Figure 6.16 Drivers and Restraints for Adacel and Other Adult Boosters, 2012
  • Figure 6.17 Adacel and Other Adult Boosters: Revenues ($bn), 2011-2022
  • Figure 6.18 Other Adult Prophylactic Vaccines: Revenues ($bn), 2011-2022
  • Figure 6.19 Summary of Leading Products in the Adult Prophylactic Vaccines Market: Revenues ($bn), 2011-2022
  • Figure 7.1 Therapeutic Vaccines Market: Revenues ($bn), 2011-2022
  • Figure 7.2 Drivers and Restraints for Therapeutic Vaccines, 2012
  • Figure 7.3 Drivers and Restraints for Provenge, 2012
  • Figure 7.4 Provenge: Revenues ($bn), 2011-2022
  • Figure 7.5 Summary of Leading Products in the Therapeutic Vaccines Market: Revenues ($bn), 2011-2022
  • Figure 10.1 Vaccine World Market Revenues ($bn), 2011-2016
  • Figure 10.2 Vaccine World Market Revenues ($bn), 2017-2022
  • Figure 10.3 Vaccine World Market Segments: Revenues ($bn), 2011-2016
  • Figure 10.4 Vaccine World Market Segments: Revenues ($bn), 2017-2022
  • Figure 10.5 Leading 10 Vaccine Franchises of 2011: Revenues ($bn), 2011-2022

Companies Listed

  • Aaron Diamond AIDS Research Center
  • Abbott Laboratories
  • Acambis
  • ACE Biosciences
  • Activartis Biotech
  • Adamis Pharmaceuticals
  • Aduro BioTech
  • Advaxis
  • Aerus Global TB Vaccine Foundation
  • Affiris
  • Agenus
  • Akela Pharma
  • ALK Abello
  • Allergy Therapeutics
  • Allertein Therapeutics
  • AlphaVax
  • Antigen Express
  • Antigenics
  • Aphton
  • Argos Therapeutics
  • Astellas Pharma US
  • AstraZeneca
  • AuRx
  • AVAX Technologies
  • Avant Immunotherapeutics
  • Baxter Healthcare
  • Bayer HealthCare
  • Bayhill Therapeutics
  • Bellicum Pharmaceuticals
  • Bharat Biotech
  • Biken Japan
  • Biogen Idec
  • Bill & Melinda Gates Foundation
  • Biomira
  • Bionor Pharma
  • BioSante Pharmaceuticals
  • Biotech Synergy
  • Biovest International
  • BN ImmunoTherapeutics (Bavarian Nordic)
  • Cancer Advances
  • CancerVax
  • Cell Control
  • Celldex Therapeutics
  • Cell Genesys
  • Celltech
  • CEL-SCI
  • Celtic Pharma
  • Centers for Disease Control and Prevention (CDC)
  • CG Therapeutics
  • Chemo-Sero-Therapeutic Research Institute
  • Chiron
  • Colby Pharmaceutical
  • Coley Pharmaceuticals
  • Corixa
  • Cosmo Pharmaceuticals
  • Crucell
  • CSL Behring
  • Cytokine PharmaSciences
  • Cytos Biotechnology
  • DBV Technologies
  • Dendreon
  • Denka Seiken
  • Department of Defense (US)
  • Dynavax Technologies
  • DynPort Vaccine
  • EMD Serono
  • Emergent BioSolutions
  • Endocyte
  • Epeius Biotechnologies
  • Etubics
  • European Medicines Agency (EMEA/EMA)
  • Evans Medica
  • Favrille
  • Food and Drug Administration (US FDA)
  • Galena Biopharma
  • GeneCure Biotechnologies
  • Genentech
  • Genetic Immunity
  • Genitope
  • GenPhar
  • GenVec
  • GeoVax Labs
  • Geron
  • GlaxoSmithKline (GSK)
  • GlobeImmune
  • Gradalis
  • Greer Laboratories
  • Hawaii Biotech
  • Heat Biologics
  • iBio
  • Ichor Medical Systems
  • immatics biotechnologies
  • Immunitor
  • ImmunoCellular Therapeutics
  • Immunocore
  • Immunofrontier
  • Immunotope
  • Immunovaccine
  • Infectious Diseases Research Institute
  • Inovio Pharmaceuticals
  • Institut Pasteur
  • Intercell
  • Intercell USA
  • International Vaccine Institute
  • Intracel
  • Inviragen
  • Janssen Alzheimer Immunotherapy
  • JN-International Medical
  • Johns Hopkins University
  • KAEL-GemVax
  • Kitasato Institute
  • LigoCyte Pharmaceuticals
  • Liquidia Technologies
  • Ludwig Institute for Cancer Research
  • MabVax Therapeutics
  • MaxCyte
  • Medeva
  • Medicago USA
  • MedImmune
  • Medirace
  • Memgen
  • Menarini
  • Merck & Co.
  • Merck KGaA
  • Meridian Biosciences
  • Momotaro-Gene
  • Nabi Biopharmaceuticals
  • NanoBio
  • Nanotherapeutics
  • National Institutes of Health (NIH, US)
  • Neurological Disorders
  • NewLink Genetics
  • Northwest Biotherapeutics
  • Novadigm Therapeutics
  • Novartis
  • NovaRx
  • Novavax
  • Novo Energies
  • NuVax Therapeutics
  • Okairos
  • Oncothyreon
  • OncoVax
  • Opal Therapeutics
  • Optimer Pharmaceuticals
  • Orban Biotech
  • Oxford BioMedica
  • PaxVax
  • Pfizer
  • PharmAthene
  • Pique Therapeutics
  • Polynoma
  • Powderject
  • Prima Biomed
  • Profectus Biosciences
  • Progenics Pharmaceuticals
  • Protein Sciences
  • Quantum Immunologics
  • Quest PharmaTech
  • Roche
  • Sabin Vaccine Institute
  • Sanaria
  • Sanofi
  • Sanofi Pasteur
  • Selecta Biosciences
  • Sinovac
  • Soligenix
  • Stallergenes
  • Stemline Therapeutics
  • Takeda
  • Teva Pharmaceutical Industries
  • The GAVI Alliance
  • Theraclone Sciences
  • Thymon
  • Transgene
  • TVAX Biomedical
  • UNICEF
  • United Biomedical
  • University of Queensland
  • University Hospital of Tubingen
  • US Naval Medical Research Center
  • Vaccine Research Center (NIAID)
  • Vaccine Technologies
  • Vaccinogen
  • Vaxart
  • VaxGen
  • Vaxin
  • VaxInnate
  • VaxOnco
  • Vical
  • WHO (World Health Organization)
  • Xcellerex

World Vaccines Market 2012-2022 published by Visiongain in July 25, 2012. This report consists of 199 Pages and the price starts from US $ 2739.

The contents of this page may be different from the latest version. Please contact us for details.
Back to Top